Iqbal S, Andersson S, Nesta E, Pentinmikko N, Kumar A, Jha SK, et al.. Fetal-like reversion in the regenerating intestine is regulated by mesenchymal asporin. Cell Stem Cell [Internet]. 2025;32(4):613 - 626.e8. https://www.sciencedirect.com/science/article/pii/S1934590925000487

Panara V, Varaliová Z, Wilting J, Koltowska K, Jeltsch M. The relationship between the secondary vascular system and the lymphatic vascular system in fish. Biological Reviews [Internet]. 2024;. https://onlinelibrary.wiley.com/doi/10.1111/brv.13114

Johns SC, Yin X, Jeltsch M, Bishop JR, Schuksz M, Ghazal REl, et al.. Functional Importance of a Proteoglycan Co-Receptor in Pathologic Lymphangiogenesis. Circulation Research [Internet]. 2016;119(2):210-221. http://circres.ahajournals.org/content/early/2016/05/25/CIRCRESAHA.116.308504

Mattonet K, Wilting J, Jeltsch M. The genetic causes of primary lymphedema. In: Weissleder H, Schuchhardt C. Erkrankungen des Lymphgefäßsystems. 6th ed. Cologne: Viavital Verlag; 2015. pp. 210-229. 

Saharinen P, Jeltsch M, Santoyo MM, Leppänen V-M, Alitalo K. The TIE Receptor Family. In: Wheeler DL, Yarden Y. Receptor Tyrosine Kinases: Family and Subfamilies [Internet]. Springer International Publishing; 2015. pp. 743-775. https://link.springer.com/content/pdf/10.1007%2F978-3-319-11888-8_16.pdf

Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, et al.. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol [Internet]. 2008;28(9):1614 - 20. http://view.ncbi.nlm.nih.gov/pubmed/18511699

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, et al.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Wedge SR, et al.. Inhibiton of VEGF-C-induced VEGFR-3 activity and lymphatic endothelial cell function by the tyrosine kinase inhibitor AZD2171. In 98th Annual Meeting of the American-Association-for-Cancer-Research [Internet]. Los Angeles, CA: American Association for Cancer Research; 2007. http://dx.doi.org/10.1158/0008-5472.CAN-07-5809

Jeltsch M, Alitalo K. VEGF Receptors. In Sigma-RBI Handbook of Receptor Classification and Signal Transduction [Internet]. 5.th ed. Sigma; 2006. http://www.sigmaaldrich.com/technical-documents/articles/biology/rbi-handbook.html

Jeltsch M, Tammela T, Alitalo K, Wilting J. Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res [Internet]. 2003;314(1):69 - 84. http://view.ncbi.nlm.nih.gov/pubmed/12942362

Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, et al.. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A [Internet]. 1998;95(2):548 - 53. http://view.ncbi.nlm.nih.gov/pubmed/9435229

Oh SJ, Jeltsch MM, Birkenhäger R, McCarthy JE, Weich HA, Christ B, et al.. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol [Internet]. 1997;188(1):96 - 109. http://view.ncbi.nlm.nih.gov/pubmed/9245515